Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2017

View Archived Issues

Bayer initiates phase I study of BAY-1895344 in advanced solid tumors and lymphomas

Dana-Farber Cancer Institute begins phase I study of rQNestin34.5v.2 for recurrent malignant glioma

TRPA1 involved in inflammation in arthritis can be inhibited by dexamethasone and aurothiomalate

Lilly and Nektar Therapeutics to co-develop NKTR-358

UCB announces promising phase IIb data for bimekizumab in patients with chronic plaque psoriasis

GSK-2878175 leads to reduction in HCV RNA in healthy and treatment-naive patients with CHC

EMA gives PRIME designation to Tocagen's Toca-511

Orchard Therapeutics' OTL-101 wins FDA rare pediatric disease designation

Seattle Genetics enters clinical collaboration with Genentech

University of Chile patents compounds for treating MDR bacterial infections

Hitgen presents histone deacetylase inhibitors

Hitgen divulges ROCK1 and ROCK2 inhibitors

Shanghai Fochon Pharmaceutical and Fochon Pharma divulge SLC22A12 inhibitors

CDK4 and CDK6 inhibitors reported in Shanghai Fochon Pharmaceutical patent

EMA committee recommends against approval of Onzeald

EMA committee recommends approval of Vimpat for focal-onset seizures in children

FDA expands Yervoy indication to include pediatric patients

FDA accepts sBLAs for Opdivo 4-week dosing schedule

GeoVax enters collaboration to advance LASV vaccine candidate

Pfizer reports results from phase III study of bevacizumab biosimilar

Evotec reaches milestone in endometriosis alliance with Bayer

Cytori Therapeutics reports topline data from STAR trial in scleroderma

Renflexis launched in U.S.

Shionogi reports phase III results on S-033188

EMA's CHMP recommends Verkazia for severe vernal keratoconjunctivitis in children and adolescents

Intrarosa launched in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...